CNS Pharmaceuticals, Inc.
CNSPHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CNS Pharmaceuticals, Inc. focuses on Biotechnology services and products. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. The $8.7M market capitalization puts CNSP squarely in micro-cap range for its industry. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Market Cap
$8.7M
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-15.23
EPS (TTM)
$-15.39
EPS (Fwd)
$-0.39
ROE
-106.6%
ROA
-58.0%
Cash
$20.0M
Total Debt
$0
Free CF
-$7.9M
52W Change
-18.1%
Annual Financials
Cash vs Debt
Where CNSP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CNSP finished 39.77% above its 150-day moving average ($4.30) and 24.17% above its 200-day moving average ($4.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNSP overbought or oversold?
At the September 3, 2026 close, CNSP's RSI(14) was 66.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CNS Pharmaceuticals, Inc. reports $20.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$7.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -106.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CNS Pharmaceuticals, Inc.'s trajectory.